Clinical trials: Obesity Overweight
Overweight or Obesity
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
This study will test olatorepatide (study drug) to determine how safe and effective this drug is and how easily your body can accept this drug without causing side effects, as well as how the drug is processed in the body by…
- Trial name
- NCT07431086
- Testing
- Olatorepatide
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Overweight and Obesity
Fixed Dose Combination of Fluoxetin and Metformin in the Management of Overweight and Obesity
Clinical trial, multicenter, double-blind, placebo-controlled, comparative of three parallel groups, randomized treatment to assess the efficacy and safety using a fixed dose combination of metformin hydrochloride with fluoxetine…
- Trial name
- Metfluo (NCT03051451)
- Testing
- combination metformin hydrochloride/ fluoxetine 500/20 mg, combination metformin hydrochloride/ fluoxetine 1000/20mg
- Where
- Mexico
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Obesity
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
The primary objective of this study is to determine the effects of ribupatide administered by subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
- Trial name
- NCT07458269
- Testing
- Ribupatide
- Where
- 35 sites in United States
- Volunteers
- 264 people
- Sponsor
- Kailera
Hyperlipidemia
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism
This study will evaluate the effects of encapsulated botanical extracts, previously shown to inhibit the enzyme diacylglycerol-acyltransferase-1 (DGAT-1) in vitro, on fasting and postprandial lipid metabolism during an oral fat…
- Trial name
- NCT02366156
- Testing
- Low Dose Grape Blend, High Dose Grape Blend
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Access Business Group
Healthy, Fatty Liver
Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease
A generic screening study to establish structural and/or functional baselines of specific organs.
- Conditions
- Healthy, Fatty Liver, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- MASLD (NCT04873258)
- Testing
- Bioimpedence Vector Analysis
- Where
- United Kingdom
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Richmond Research Institute
Obesity
Signature Diagnostic of Non-alcoholic Steatohepatitis (NASH) by Infrared Light Spectroscopy
Evaluation of the diagnostic performance of an algorithm developed to detect metabolic profiles specific of non-alcoholic steatohepatitis NASH and based on the reading of a blood sample's infrared spectra
- Trial name
- SIGNALS (NCT03978247)
- Testing
- NASHMIR
- Where
- Belgium
- Volunteers
- 382 people
- Sponsor
- Diafir
Obesity
WEgovy Real World Assessment of Weight Loss in Korea
This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice.
- Trial name
- NCT07280221
- Testing
- Semaglutide
- Where
- 18 sites in South Korea
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Obesity, Over-weight
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics for certain doses of beloranib in obese subjects with Prader-Willi Syndrome.
- Conditions
- Obesity, Over-weight, Prader-Willi Syndrome
- Trial name
- NCT01818921
- Testing
- ZGN-440 sterile diluent, 1.2 mg ZGN-440 for injectable suspension, 1.8 mg ZGN-440 for injectable suspension
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Zafgen, Inc.
Overweight, Obesity
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.
- Trial name
- NCT06047548
- Testing
- Tirzepatide
- Where
- 20 sites in United States
- Volunteers
- 441 people
- Sponsor
- Eli Lilly and Company
Obesity
Effects of Red Light LED Therapy on Body Contouring
The purpose of this study is to determine whether red light therapy using LED 650nm red light for body contouring of the waist, hips and thighs is as effective as red light therapy using Laser 635nm red light.
- Trial name
- NCT03242564
- Testing
- Vevazz LED
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Vevazz, LLC
Overweight, Obesity
A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control
This is a randomized, double-blind, placebo-controlled, decentralized clinical trial evaluating the effects of MN Nutra GeLiPthin-1™, a multi-ingredient dietary supplement, on body weight, BMI, waist circumference, appetite…
- Conditions
- Overweight, Obesity, Weight Management, Appetite Control
- Trial name
- NCT07895563
- Testing
- MN Nutra GeLiPthin-1™ Dietary Supplement
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- MNnutra
Overweight or Obesity
Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity.
- Trial name
- NCT07594093
- Testing
- REGN20934
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Obese
Safety and Pharmacokinetics of HU6
Part 1 is an open-label, randomized, Latin-square 2x2 crossover study. Twelve subjects will be randomized (1:1) to treatment sequence to determine the order in which they will receive the tablet or capsule formulation in Period 1…
- Trial name
- NCT05433506
- Testing
- HU6 Tablet, HU6 Capsule
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Rivus Pharmaceuticals, Inc.
Obesity, Overweight
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or…
- Trial name
- NCT07607587
- Testing
- Cagrilintide
- Where
- 13 sites in United States
- Volunteers
- 114 people
- Sponsor
- Novo Nordisk A/S
Insulin Resistance, Obesity
Pilot Study of GLY-LOW Supplementation in Postmenopausal Women With Obesity
A combination of generally regarded as safe (GRAS) compounds named GLY-LOW, which included: alpha lipoic acid, pyridoxamine, nicotinamide, piperine and thiamine, were examined in pre-clinical experiments.
- Conditions
- Insulin Resistance, Obesity, Cardiovascular Diseases, Cognitive Impairment
- Trial name
- NCT06242535
- Testing
- GLY-LOW
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Hoskinson Health and Wellness Clinic
Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight (BMI > 25)
AIM-WEIGHT: AI-Guided Microbiome-Targeted Nutritional Intervention for Weight Loss
AIM-WEIGHT is a clinical study evaluating whether a fixed microbiome-targeted nutritional supplement can support weight loss in adults with overweight or obesity who do not have prediabetes or diabetes.
- Trial name
- AIM-WEIGHT (NCT07736547)
- Testing
- AI-Guided Microbiome-Targeted Nutritional Supplement, Lifestyle counselling
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Varol TUNALI
Overweight, Obesity
Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
A randomized, double-blind, placebo-controlled, dose-ranging study to examine the safety, tolerability and effect on body weight of a range of doses of metreleptin and pramlintide, each administered by a separate subcutaneous…
- Trial name
- NCT00673387
- Testing
- pramlintide acetate, metreleptin
- Where
- 36 sites in United States
- Volunteers
- 636 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Anxiety about needles is a concern commonly expressed by diabetics when beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of longer pen needles may appeal to many…
- Trial name
- NCT01231984
- Testing
- 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
- Where
- 10 sites in United States
- Volunteers
- 293 people
- Sponsor
- Becton, Dickinson and Company
Overweight, Obesity
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication
The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of semaglutide in people with overweight or obesity, with or without type 2 diabetes (T2D).
- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Trial name
- NCT07855133
- Testing
- Semaglutide, Zenagamtide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Obesity
Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMF-650 in Otherwise Healthy Overweight or Obese…
- Trial name
- NCT07223216
- Testing
- BMF-650
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Biomea Fusion Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.